Aims The aim of this study was to examine the bioequivalence between a single oral dose of digoxin administered alone and with a coadministration of macrogol 4000 (a laxative polymer) in 18 healthy volunteers. Methods This was an open, randomised, two-way cross-over study, with a single dose oral administration of 0.5 mg digoxin administered alone or in combination with macrogol 4000, 20 g day −1 during 8 days. Pharmacokinetics of digoxin, heart rate and PR ECG interval at rest were assessed. Results Macrogol 4000 coadministration was associated with a 30% decrease of digoxin AUC and a 40% decrease in its C max ( P<0.05). Digoxin t max and t 1/2,z were not significantly altered. Heart rate and PR interval did not differ during the two therapeutic sequences, digoxin alone and digoxin in combination.
Introduction study was to assess a possible influence of macrogol 4000 on the pharmacokinetic profile of digoxin. Macrogol 4000 (ForlaxA), a laxative polymer, has been registered for the symptomatic treatment of functional constipation at the dosage of 10-20 g daily. Macrogol
Methods 4000 is not absorbed; it increases the osmotic pressure in the gut. These osmotic effects could induce modifications Study design in intestinal resorption of drugs.
Eighteen healthy volunteers (10 males and 8 females) Digoxin is a cardiac glycoside commonly used in the aged 22 years (19-36) were included in a double-blind, treatment of congestive heart failure and atrial dys-2-period cross-over trial after giving their written rhythmias, mainly eliminated by kidneys as unchanged informed consent to participate. Local Ethics Committee drug with a long elimination half-life of approximately approval for the study was obtained. The two therapeutic 36 h (range: 30-40 h) [1] . The intestinal absorption of sequences were performed in a randomised order and digoxin is incomplete, dependent upon formulation were separated by 11-25 days of washout. During one characteristics and highly variable between individuals [2].
period, subjects received a single oral dose of 0.5 mg The therapeutic range of plasma concentrations of digoxin digoxin (2 tablets of Digoxin NativelleA). During the is 0.8 ng ml −1 to 2.0 ng ml
other period, they received the same dose of digoxin Since an alteration in absorption of concomitantly coadministered with 20 g macrogol 4000, preceded administered drugs is theoretically possible with macrogol (4 days) and followed (3 days) by single administrations 4000, and because digoxin is a widely prescribed drug of macrogol 4000, at the dosage of 20 g day −1 .
Blood samples for digoxin level determination were 58, 72, 82, 96, and 120 h after drug administration. The Results day of digoxin administration, 12-lead ECG were recorded at the same evaluation times as plasma samples Pharmacokinetics for determination of heart rate (RR interval) and PR Figure 1 shows the time course profile of mean plasma interval at rest. Subjects were hospitalized during the first concentrations of digoxin obtained with and without 24 h following oral administration of digoxin. macrogol 4000. The pharmacokinetic parameters are summarized in Table 1 oxin elimination half-life was not significantly different The following parameters were calculated for each period:
in the absence and the presence of macrogol 4000 time of plasma peak appearance (t max , h), maximum (33.8±8.8 h and 30.7±10.2 h, respectively). plasma concentration (C max , ng ml −1 ), area under plasma concentration time curve calculated from time 0 to the Pharmacodynamic parameters last sampling time (t) and from 0 to infinity (AUC(0,t) and AUC(0, 2) ng ml −1 h) by the linear trapezoidal No modification of AV conduction under treatment was method, and apparent elimination half-life (t 1/2,z , h).
observed over the 24 h hospitalization between the two therapeutic sequences. We observed a bradycardic effect during the first 6 h following the digoxin administration, with a maximal decrease of 18.9±8.1% alone and Pharmacodynamic parameters 16.9±8.6% in combination (NS). Heart rate and PR interval at rest were calculated, for each ECG recording at 50 mm s −1 , from three consecutive QRS intervals, using a digitizing table (SummaSketch Professional MM II 1812, Summagraphics, Seymour, CT USA).
Statistical analysis
The pharmacokinetic parameters of digoxin with and without coadministration of macrogol 4000 were compared by using an analysis of variance (anova) for a twoperiod crossover design and a Dunnett-test (at the 0.05 significance level). Two one-sided tests bioequivalence decision rule for log-transformed data was applied to compare the magnitude of the differences observed in C max and AUC. The accepted bioequivalence limits of the 90% confidence interval of the geometric mean ratio were 0.80-1.25. Experimental t max were compared by using the sign test. The maximal effects on heart rate and AV conduction observed under treatment were compared sidered to be statistically significant at P<0.05. [12] . These results could be explainPharmacokinetics ed by the low dose of digoxin tested, which is below the The digoxin pharmacokinetic parameters observed in our loading dose required to achieve a full therapeutic effect. study are in accordance with those found in the literature in healthy volunteers with comparable doses [7, 8] . We
Clinical implications observed a statistically significant difference between the two therapeutic sequences for the C max and AUC values, Although there is considerable debate on the plasma without any difference for t max , suggesting that macrogol concentration-effect relationships during digoxin acute 4000 coadministration interacts with single-dose digoxin and chronic treatment [1, 5], a decrease in digoxin pharmacokinetics by reducing the absorption of the drug.
digestive absorption could result in loss of therapeutic These data are in accordance with the results of Padoin effect. We did not observe any reduction in the et al. who previously showed a decreased amoxicillin pharmacodynamic response following a single dose absorption with a coadministration of saline-macrogol in administration of 0.5 mg digoxin in normal subjects. The healthy volunteers [9] .
pharmacokinetic interaction observed in this study has to Macrogol 4000 is not absorbed and has a local osmotic be evaluated in patients during chronic digoxin treatment intestinal action. Thus, the decreased absorption rate of in order to assess the therapeutic consequences of this digoxin observed in our study could be explained by a drug-drug interaction. decreased concentration at the absorption site, resulting This study was supported by a grant in aid from BEAUFOUR from an increased volume of liquid in the intestinal Laboratories lumen caused by macrogol 4000, or by local changes in pH or electrolytes. However, no effect on stool hydratation, stool electrolytes output and pH has been References found in healthy volunteers treated by low doses of 1 Cheymol G, Jaillon P. Heterosides cardiotoniques. Sem Hôp macrogol 4000 [10] . Another hypothesis could be a direct conduction were observed in the subjects. Similar results
